SS-31
Aeterna does not sell peptides. External link, vendor independently verified.
Mechanism
SS-31 does not act on a receptor in the conventional sense. It does not bind a surface protein or trigger a downstream signaling cascade in the manner of most peptide therapeutics. Instead, it enters the cell, crosses the inner mitochondrial membrane, and binds directly to cardiolipin – a phospholipid found almost exclusively in that membrane and essential to the structural integrity of the electron transport chain. The conversation it initiates is architectural, not chemical. It restores the geometry of energy production.
Membrane targeting SS-31 localizes to the inner mitochondrial membrane, where it associates with cardiolipin and helps stabilize cristae architecture. This interaction supports electron transport chain efficiency under conditions of oxidative stress.
Energetic preservation Rather than acting as a conventional direct antioxidant, the peptide appears to reduce reactive oxygen species by improving electron flow through the respiratory chain. In preclinical models, this is associated with more efficient ATP production during ischemia-reperfusion stress.
Clinical development SS-31, also known as elamipretide, is among the most clinically advanced mitochondria-targeted peptides. It has been studied in disorders including Barth syndrome and heart failure, with subcutaneous and intravenous protocols evaluated across trials.
Translational signal The strongest preclinical evidence has emerged in cardiac, skeletal muscle, renal, and mitochondrial disease contexts. Human efficacy signals have been mixed, but the compound remains a central reference point in mitochondrial therapeutics research.
What we observe
Energy and recovery: what changed
The evidence base for SS-31 spans two decades of preclinical work and a smaller but growing body of human clinical data. The compound has been studied under multiple designations – SS-31, MTP-131, elamipretide – across cardiac, renal, neuromuscular, and metabolic contexts. What follows reflects patterns reported in peer-reviewed literature; it does not constitute a claim of efficacy for any individual.
01
Cardiac Energetics
02
Ischemia Reperfusion Protection
03
Skeletal Muscle Function
04
Renal Tubular Protection
05
Neurological Resilience
06
Barth Syndrome
Evidence
SS-31 in trials and lab work
The studies below represent a cross-section of the published evidence. They are cited for orientation, not as proof of clinical efficacy. Readers are encouraged to consult primary sources and to weigh findings against study design, sample size, and the distance between animal models and human physiology.
Elamipretide Improves Mitochondrial Function and Exercise Tolerance in Patients with Heart Failure with Preserved Ejection Fraction: The MMPOWER-HF Pilot Trial
In a randomized, double-blind, placebo-controlled pilot study of 42 patients with HFpEF, a single intravenous infusion of elamipretide (SS-31) was associated with significant improvements in peak oxygen consumption (VO₂ peak) and six-minute walk distance at 24 hours post-infusion. Mitochondrial respiration in peripheral blood mononuclear cells improved in the treatment arm. No serious adverse events were attributed to the compound.
SS-31 Preserves Cardiolipin Architecture and Prevents Cytochrome c Release in a Murine Model of Renal Ischemia-Reperfusion Injury
Using electron microscopy and cardiolipin-specific fluorescent probes, investigators demonstrated that SS-31 administered 30 minutes prior to ischemia preserved inner mitochondrial membrane cristae morphology, reduced cardiolipin peroxidation by approximately 60%, and prevented cytochrome c translocation to the cytosol. Serum creatinine at 24 hours post-reperfusion was significantly lower in treated animals, and histological tubular injury scores were reduced by more than half.
Long-Term SS-31 Administration Attenuates Age-Associated Mitochondrial Dysfunction and Preserves Skeletal Muscle Mass in Aged Mice
Twenty-four-month-old C57BL/6 mice receiving daily subcutaneous SS-31 for 8 weeks showed significant preservation of gastrocnemius muscle mass, improved grip strength, and restored mitochondrial membrane potential compared to age-matched controls. Electron microscopy revealed partial restoration of cristae density. Markers of mitochondrial biogenesis (PGC-1α, TFAM) were elevated in treated animals, suggesting a secondary adaptive response beyond direct cardiolipin stabilization.
From lyophilized powder to a usable solution.
Peptide
10 mg lyophilized powder
Diluent
1.0 mL bacteriostatic water
Final concentration
10 mg/mL
01
Prepare the vial
02
Draw the diluent
03
Add slowly
04
Prepare the vial
Note
Dosing rythm
A patient titration
Schedule below mirrors the peptidedosages.com educational protocol (typical daily range: 5–10 mg once daily (gradual titration); advanced protocols may reach 15–20 mg/day under supervision).
Storage, caution, contradiction
Storage
Cold, dark, undisturbed
- Lyophilized: freeze at −20 °C (−4 °F).
- After reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F).
- Use within 4 weeks.
- SS-31 is relatively stable in aqueous solution at physiological pH; avoid strongly acidic or alkaline conditions during preparation.
- Do not expose reconstituted solution to prolonged room temperature; the short plasma half-life reflects metabolic clearance, not instability, but thermal degradation of the peptide itself can occur above 25°C over extended periods.
Side effects
What members describe
- Injection site reactions - mild erythema, transient discomfort, or induration - are the most commonly reported adverse events in subcutaneous administration protocols; rotating injection sites is standard practice.
- Nausea and mild gastrointestinal discomfort have been reported in a minority of subjects in IV infusion trials, typically resolving within hours of infusion completion.
- Transient hypotension has been observed during rapid IV administration; slow infusion rates (over 2 hours) are standard in clinical protocols to mitigate this risk.
- Headache and fatigue have been noted in a small proportion of trial participants; causality attribution is complicated by the underlying disease populations studied.
- No significant hepatotoxicity, nephrotoxicity, or hematological abnormalities have been reported in completed trials to date; the safety profile across Phase I and II studies has been described as favorable.
Contradictions
Reasons to abstain
- Known hypersensitivity to any component of the SS-31 formulation, including the D-amino acid residues or the amidated C-terminus.
- Pregnancy and lactation: no human safety data exist; animal reproductive toxicology studies are limited; use is not supported in these populations outside of carefully supervised investigational contexts.
- Concurrent use with agents that significantly alter mitochondrial membrane potential (e.g., certain antifungals, aminoglycosides at nephrotoxic doses) warrants caution; pharmacodynamic interactions are theoretically possible but not well-characterized.
- Severe hepatic impairment: metabolic clearance pathways are not fully characterized; dose adjustment guidance does not exist in the current literature.
- Self-administration without medical supervision is not supported by the available evidence base; the investigational status of SS-31 in all jurisdictions means that administration outside a clinical or closely supervised research context carries unquantified risk.
Synergies
What to stack with SS-31
SS-31 occupies a distinct position in the peptide landscape: it acts at the organelle level rather than the receptor level. Its natural companions are agents that address upstream metabolic signaling, downstream cellular repair, or parallel pathways of oxidative stress and inflammation. The combinations below reflect mechanistic logic and patterns in the preclinical literature – not clinical protocols.
FAQ
Your questions, patiently answered
Most antioxidants – vitamin C, vitamin E, CoQ10 – act in the cytosol or at the cell membrane. SS-31 concentrates at the inner mitochondrial membrane, the precise site where reactive oxygen species are generated during electron transport. Its affinity for cardiolipin means it is positioned where the damage originates, not downstream of it. This spatial specificity is what separates it mechanistically from broad-spectrum antioxidant supplementation.
Cardiolipin is a structural phospholipid found almost exclusively in the inner mitochondrial membrane. It is not merely a passive component of the lipid bilayer – it actively organizes the respiratory chain supercomplexes (respirasomes) that make oxidative phosphorylation efficient. When cardiolipin is peroxidized or its remodeling is disrupted (as in Barth syndrome), the entire architecture of ATP production is compromised. SS-31’s affinity for cardiolipin is therefore a direct engagement with the structural foundation of cellular energy.
They are the same molecule. SS-31 is the original laboratory designation from the Szeto-Schiller peptide series. MTP-131 was the designation used in early clinical development. Elamipretide is the International Nonproprietary Name (INN) assigned for clinical and regulatory purposes. Stealth BioTherapeutics advanced the compound under the elamipretide designation in its cardiac and mitochondrial disease programs.
Stealth BioTherapeutics completed several Phase II and Phase III trials, including MMPOWER-3 in primary mitochondrial myopathy and the SPEED trial in Barth syndrome. The MMPOWER-3 trial did not meet its primary endpoint (six-minute walk distance) in the full population, though pre-specified subgroup analyses suggested benefit in patients with greater baseline functional impairment. The company subsequently restructured. The compound’s clinical story is ongoing – the mechanistic rationale remains intact, and investigational interest continues in academic and independent research settings.
The preclinical literature in aged animal models is suggestive. Mitochondrial dysfunction – characterized by reduced membrane potential, increased ROS production, and cardiolipin peroxidation – is a consistent feature of cellular aging across tissues. SS-31 administration in aged rodents has been associated with improvements in muscle function, cardiac energetics, and markers of mitochondrial biogenesis. Whether these observations translate to meaningful benefit in healthy aging humans is an open question. The mechanism is plausible; the human evidence is absent.
It does not. Aeterna Method is an educational practice. We do not prescribe, dispense, or sell SS-31 or any other compound. This monograph exists to translate the available science into a coherent reference for those who wish to understand the peptide before engaging with a qualified clinician or researcher. The decision to pursue any investigational compound belongs to the individual and their physician – not to us.
In the same family
Further reading in the curriculum.
Sourcing · Independently verified
When you're ready, source thoughtfully.